{"product_id":"amgn-business-model-canvas","title":"Amgen Inc. (AMGN): Business Model Canvas [June-2026 Updated]","description":"\u003cp\u003eThis ready-made Business Model Canvas of Amgen Inc. gives you a practical, research-based view of how the company creates, delivers, and captures value through oncology, rare disease, bone, cardiovascular, and immunology products, biosimilars, and international sales. You'll see the core drivers behind its business model, including \u003cstrong\u003e273\u003c\/strong\u003e clinical studies, heavy R\u0026amp;D, biologics manufacturing, regulatory approvals in the US and EU, physician and specialist relationships, hospitals and specialty pharmacies as channels, strong cash flow, and key partnerships across trial sites, supply-chain partners, regulators, and a \u003cstrong\u003e2026\u003c\/strong\u003e sports partnership.\u003c\/p\u003e\u003ch2\u003eAmgen Inc. - Canvas Business Model: Key Partnerships\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$28.190 billion\u003c\/strong\u003e in 2023 revenue and \u003cstrong\u003e$4.511 billion\u003c\/strong\u003e in 2023 R\u0026amp;D spending show the scale behind Amgen Inc.'s partner network.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003ePartnership area\u003c\/td\u003e\n\u003ctd\u003ePublicly disclosed count\u003c\/td\u003e\n\u003ctd\u003eLatest public status\u003c\/td\u003e\n\u003ctd\u003eBusiness-model role\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOpenAI enterprise AI tools\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e0 public Amgen deal disclosed\u003c\/td\u003e\n\u003ctd\u003eResearch and operations support\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical trial sites and investigators\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e0 company-level site count disclosed\u003c\/td\u003e\n\u003ctd\u003eEnrollment, data collection, protocol execution\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing and supply-chain partners\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e0 public named external partner count disclosed\u003c\/td\u003e\n\u003ctd\u003eDrug substance, fill-finish, packaging, logistics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEuropean Commission and global regulators\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEuropean Commission, European Medicines Agency, U.S. Food and Drug Administration, Pharmaceuticals and Medical Devices Agency, Medicines and Healthcare products Regulatory Agency\u003c\/td\u003e\n\u003ctd\u003eApproval, inspection, labeling, market access\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eFIFA World Cup 2026 sports partnership\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e0\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e0 public Amgen sponsorship disclosed\u003c\/td\u003e\n\u003ctd\u003eBrand exposure\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$28.190 billion\u003c\/strong\u003e revenue\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$4.511 billion\u003c\/strong\u003e R\u0026amp;D\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e0\u003c\/strong\u003e public Amgen-OpenAI enterprise contract disclosure\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e0\u003c\/strong\u003e public Amgen-FIFA World Cup 2026 sponsorship disclosure\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e0\u003c\/strong\u003e public named external manufacturing partner count disclosure\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e0\u003c\/strong\u003e public company-level trial site count disclosure\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eEuropean Commission\u003c\/p\u003e\n\u003cp\u003eEuropean Medicines Agency\u003c\/p\u003e\n\u003cp\u003eU.S. Food and Drug Administration\u003c\/p\u003e\n\u003cp\u003ePharmaceuticals and Medical Devices Agency\u003c\/p\u003e\n\u003cp\u003eMedicines and Healthcare products Regulatory Agency\u003c\/p\u003e\u003ch2\u003eAmgen Inc. - Canvas Business Model: Key Activities\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e273\u003c\/strong\u003e studies, \u003cstrong\u003e28,000\u003c\/strong\u003e employees, \u003cstrong\u003e100+\u003c\/strong\u003e countries, and \u003cstrong\u003e$33.4B\u003c\/strong\u003e in 2024 revenue define the activity base behind Amgen Inc.'s business model.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eKey activity\u003c\/th\u003e\n\u003cth\u003eReal-life figure\u003c\/th\u003e\n\u003cth\u003eYear or scope\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDrug discovery and R\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e273\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eStudies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eClinical trials\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e273\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eStudies\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlobal regulatory reach\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e100+\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCountries\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiologics manufacturing and scale-up\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e28,000\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eEmployees\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCommercialization and market access\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$33.4B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e2024 revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eDrug discovery and R\u0026amp;D:\u003c\/strong\u003e \u003cstrong\u003e273\u003c\/strong\u003e studies sit at the center of the development engine.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e273\u003c\/strong\u003e studies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e28,000\u003c\/strong\u003e employees.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e revenue: \u003cstrong\u003e$33.4B\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eClinical trials across 273 studies:\u003c\/strong\u003e \u003cstrong\u003e273\u003c\/strong\u003e studies.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e273\u003c\/strong\u003e studies.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e100+\u003c\/strong\u003e countries.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eGlobal regulatory filings and approvals:\u003c\/strong\u003e \u003cstrong\u003e100+\u003c\/strong\u003e countries.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e100+\u003c\/strong\u003e countries.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e273\u003c\/strong\u003e studies.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eBiologics manufacturing and scale-up:\u003c\/strong\u003e \u003cstrong\u003e28,000\u003c\/strong\u003e employees.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e28,000\u003c\/strong\u003e employees.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2024\u003c\/strong\u003e revenue: \u003cstrong\u003e$33.4B\u003c\/strong\u003e.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCommercialization and market access:\u003c\/strong\u003e \u003cstrong\u003e$33.4B\u003c\/strong\u003e revenue and \u003cstrong\u003e100+\u003c\/strong\u003e countries.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e$33.4B\u003c\/strong\u003e revenue in \u003cstrong\u003e2024\u003c\/strong\u003e.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e100+\u003c\/strong\u003e countries.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e28,000\u003c\/strong\u003e employees.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eAmgen Inc. - Canvas Business Model: Key Resources\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003eAmgen Inc.'s key resources are built around a \u003cstrong\u003e$33.4B\u003c\/strong\u003e revenue base, \u003cstrong\u003e$4.8B\u003c\/strong\u003e of R\u0026amp;D spending, a \u003cstrong\u003e$27.8B\u003c\/strong\u003e acquisition, and about \u003cstrong\u003e28,000\u003c\/strong\u003e employees.\u003c\/strong\u003e Those numbers show a capital-intensive biotech model that depends on approved medicines, late-stage development, global production, and financing capacity.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eKey resource\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eReal-life number\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eResource role\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$33.4B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eFunds the portfolio, trials, manufacturing, and debt service.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spending\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.8B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eSupports late-stage pipeline work and data-driven development.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHorizon Therapeutics acquisition\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$27.8B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eExpanded the asset base and future cash flow mix.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eWorkforce\u003c\/td\u003e\n\u003ctd\u003eAbout \u003cstrong\u003e28,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSupports research, quality, regulatory, and commercial execution.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing footprint\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e major geographies\u003c\/td\u003e\n\u003ctd\u003eHelps protect supply continuity for biologics.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eBranded biologic portfolio\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe portfolio is the core resource because it turns approved medicines into recurring sales. Amgen Inc. reported \u003cstrong\u003e$33.4B\u003c\/strong\u003e in revenue in 2024, so the company's business model still depends on products already in the market rather than only on future approvals. In a biologics business, this matters because each approved product can support years of manufacturing, pricing, and lifecycle management. For academic writing, this is the clearest example of how intellectual property becomes cash flow.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eLate-stage pipeline\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAmgen Inc. spent \u003cstrong\u003e$4.8B\u003c\/strong\u003e on research and development in 2024. That spending is the clearest public measure of its late-stage pipeline resource, because it covers clinical development, regulatory work, and data generation. The pipeline matters strategically because it replaces revenue when mature products face loss of exclusivity, pricing pressure, or slower growth. A company with this level of R\u0026amp;D spending can keep more programs moving at the same time than a smaller biotech can.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eAI and data science capabilities\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eAmgen Inc. does not report a separate AI budget line, so the public number that best captures this resource is still the \u003cstrong\u003e$4.8B\u003c\/strong\u003e R\u0026amp;D base. AI and data science sit inside that spending and support target selection, trial design, and manufacturing analytics. This matters because better data use can reduce failed experiments, improve program selection, and help the company direct capital toward the most promising assets.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eGlobal manufacturing network\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe manufacturing resource is a regulated production system rather than a single plant. Amgen Inc. operates across the United States, Ireland, Puerto Rico, and Singapore. That geographic spread matters because biologics are harder to make than small-molecule drugs, and supply disruptions can hurt revenue fast. The network also supports quality control, redundancy, and scaling when a product grows quickly after launch.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e4\u003c\/strong\u003e major geographies for manufacturing and supply support.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$33.4B\u003c\/strong\u003e in 2024 revenue gives production assets a large commercial base.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$4.8B\u003c\/strong\u003e in R\u0026amp;D keeps the manufacturing pipeline linked to future launches.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eStrong cash flow and balance sheet\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eThe balance sheet became more important after the \u003cstrong\u003e$27.8B\u003c\/strong\u003e Horizon Therapeutics acquisition. Large cash generation matters because it funds R\u0026amp;D, supports capital spending, and helps service debt without depending on equity markets. For a biologics company, this is a key resource because product development and plant investment both need long funding horizons. Revenue of \u003cstrong\u003e$33.4B\u003c\/strong\u003e gives Amgen Inc. scale, while the acquisition size shows how much financial capacity the company needs to keep expanding.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eFinancial resource\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eAmount\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eWhat it supports\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$33.4B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eCommercial scale and reinvestment capacity.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$4.8B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003eLate-stage pipeline and data science work.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcquisition size\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e$27.8B\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003ePortfolio expansion and future cash flow diversification.\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eAbout 28,000\u003c\/strong\u003e employees support these resources across research, manufacturing, quality, regulatory, and commercial functions. That headcount matters because it shows Amgen Inc. is operating at the scale of a large pharmaceutical company, not a small research-stage biotech.\u003c\/p\u003e\u003ch2\u003eAmgen Inc. - Canvas Business Model: Value Propositions\u003c\/h2\u003e\n\u003cp\u003eAmgen's 2024 revenue was \u003cstrong\u003e$33.424 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eInnovative therapies in oncology and rare disease\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eImdelltra received U.S. FDA approval in \u003cstrong\u003e2024\u003c\/strong\u003e for extensive-stage small cell lung cancer after platinum-based chemotherapy. The pivotal data showed a \u003cstrong\u003e40%\u003c\/strong\u003e confirmed overall response rate and a \u003cstrong\u003e9.7-month\u003c\/strong\u003e median duration of response.\u003c\/p\u003e\n\u003cp\u003eBlincyto has a measurable survival profile in B-cell precursor acute lymphoblastic leukemia. In the TOWER study, median overall survival was \u003cstrong\u003e7.7 months\u003c\/strong\u003e versus \u003cstrong\u003e4.0 months\u003c\/strong\u003e, and complete remission or complete remission with partial hematologic recovery was \u003cstrong\u003e34%\u003c\/strong\u003e versus \u003cstrong\u003e16%\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eAmgen completed the Horizon Therapeutics acquisition in \u003cstrong\u003e2023\u003c\/strong\u003e for \u003cstrong\u003e$27.8 billion\u003c\/strong\u003e. Tepezza is given as \u003cstrong\u003e8\u003c\/strong\u003e infusions over \u003cstrong\u003e24 weeks\u003c\/strong\u003e. Krystexxa is dosed every \u003cstrong\u003e2 weeks\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eLeading bone, cardiovascular, and immunology brands\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eBrand\u003c\/th\u003e\n\u003cth\u003eTherapy area\u003c\/th\u003e\n\u003cth\u003eReal-life numerical value proposition\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProlia\u003c\/td\u003e\n\u003ctd\u003eBone\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e60 mg\u003c\/strong\u003e every \u003cstrong\u003e6 months\u003c\/strong\u003e; \u003cstrong\u003e68%\u003c\/strong\u003e lower risk of new vertebral fractures; \u003cstrong\u003e20%\u003c\/strong\u003e lower nonvertebral fracture risk; \u003cstrong\u003e40%\u003c\/strong\u003e lower hip fracture risk\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvenity\u003c\/td\u003e\n\u003ctd\u003eBone\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e210 mg\u003c\/strong\u003e once monthly for \u003cstrong\u003e12 months\u003c\/strong\u003e; \u003cstrong\u003e73%\u003c\/strong\u003e lower risk of new vertebral fractures at \u003cstrong\u003e12 months\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRepatha\u003c\/td\u003e\n\u003ctd\u003eCardiovascular\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e140 mg\u003c\/strong\u003e every \u003cstrong\u003e2 weeks\u003c\/strong\u003e or \u003cstrong\u003e420 mg\u003c\/strong\u003e monthly; \u003cstrong\u003e59%\u003c\/strong\u003e LDL-C reduction; \u003cstrong\u003e15%\u003c\/strong\u003e reduction in major cardiovascular events\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEnbrel\u003c\/td\u003e\n\u003ctd\u003eImmunology\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e50 mg\u003c\/strong\u003e weekly\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTezspire\u003c\/td\u003e\n\u003ctd\u003eImmunology\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e210 mg\u003c\/strong\u003e every \u003cstrong\u003e4 weeks\u003c\/strong\u003e; \u003cstrong\u003e56%\u003c\/strong\u003e reduction in annualized asthma exacerbations\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eConvenient dosing innovations\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eProlia: \u003cstrong\u003e1\u003c\/strong\u003e dose every \u003cstrong\u003e6 months\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eEvenity: \u003cstrong\u003e12\u003c\/strong\u003e monthly doses\u003c\/li\u003e\n\u003cli\u003eRepatha: \u003cstrong\u003e140 mg\u003c\/strong\u003e every \u003cstrong\u003e2 weeks\u003c\/strong\u003e or \u003cstrong\u003e420 mg\u003c\/strong\u003e monthly\u003c\/li\u003e\n\u003cli\u003eAimovig: \u003cstrong\u003e70 mg\u003c\/strong\u003e or \u003cstrong\u003e140 mg\u003c\/strong\u003e monthly\u003c\/li\u003e\n\u003cli\u003eTezspire: \u003cstrong\u003e210 mg\u003c\/strong\u003e every \u003cstrong\u003e4 weeks\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eNeulasta Onpro: drug delivery begins about \u003cstrong\u003e27 hours\u003c\/strong\u003e after application\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eGlobal access through new approvals\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003eImdelltra added a \u003cstrong\u003e2024\u003c\/strong\u003e U.S. approval to the portfolio. Horizon Therapeutics added a \u003cstrong\u003e2023\u003c\/strong\u003e rare-disease platform for \u003cstrong\u003e$27.8 billion\u003c\/strong\u003e.\u003c\/p\u003e\n\u003cp\u003eTepezza uses an \u003cstrong\u003e8\u003c\/strong\u003e-infusion regimen over \u003cstrong\u003e24 weeks\u003c\/strong\u003e. Krystexxa is dosed every \u003cstrong\u003e2 weeks\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cp\u003e\u003cstrong\u003eBiosimilar and life-cycle management expertise\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eAmjevita launched in the U.S. in \u003cstrong\u003e2023\u003c\/strong\u003e as the first adalimumab biosimilar to reach the market there\u003c\/li\u003e\n\u003cli\u003eNeulasta Onpro combines a \u003cstrong\u003e6 mg\u003c\/strong\u003e dose with automated delivery about \u003cstrong\u003e27 hours\u003c\/strong\u003e after application\u003c\/li\u003e\n\u003cli\u003eEnbrel remains a \u003cstrong\u003e50 mg\u003c\/strong\u003e weekly regimen\u003c\/li\u003e\n\u003cli\u003eProlia remains a \u003cstrong\u003e6-month\u003c\/strong\u003e regimen\u003c\/li\u003e\n\u003cli\u003eRepatha remains a \u003cstrong\u003e2-week\u003c\/strong\u003e or \u003cstrong\u003emonthly\u003c\/strong\u003e regimen\u003c\/li\u003e\n\u003cli\u003eEvenity remains a \u003cstrong\u003e12-month\u003c\/strong\u003e regimen\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eAmgen Inc. - Canvas Business Model: Customer Relationships\u003c\/h2\u003e\n\u003cp\u003eAmgen's customer relationships are built around specialist prescribers, patient access support, safety follow-up, and research partnerships. The company reported \u003cstrong\u003e$28.2 billion\u003c\/strong\u003e in net sales in 2023 and sells products in more than \u003cstrong\u003e100\u003c\/strong\u003e countries, so relationship quality affects both prescription volume and long-term treatment persistence.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eRelationship channel\u003c\/td\u003e\n\u003ctd\u003ePrimary customer group\u003c\/td\u003e\n\u003ctd\u003eWhat Amgen does\u003c\/td\u003e\n\u003ctd\u003eWhy it matters\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePhysician and specialist engagement\u003c\/td\u003e\n\u003ctd\u003eOncologists, hematologists, rheumatologists, nephrologists, cardiologists, endocrinologists\u003c\/td\u003e\n \u003ctd\u003eScientific exchange, field support, congress activity, clinical education\u003c\/td\u003e\n \u003ctd\u003eThese specialists decide initiation, switching, dosing, and monitoring for most therapies\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePatient access support via AmgenNow\u003c\/td\u003e\n\u003ctd\u003ePatients, caregivers, specialty offices, patient support staff\u003c\/td\u003e\n \u003ctd\u003eBenefits verification, prior authorization support, coverage navigation, financial assistance\u003c\/td\u003e\n \u003ctd\u003eReduces delays between prescription and treatment start\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMedical affairs and market access teams\u003c\/td\u003e\n\u003ctd\u003ePayers, PBMs, hospital systems, integrated delivery networks, clinicians\u003c\/td\u003e\n \u003ctd\u003eClinical evidence, health economics, reimbursement discussions, medical information\u003c\/td\u003e\n \u003ctd\u003eCoverage and formulary access affect realized demand\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOngoing post-launch safety monitoring\u003c\/td\u003e\n\u003ctd\u003ePatients, physicians, regulators\u003c\/td\u003e\n\u003ctd\u003eAdverse event reporting, signal detection, post-marketing surveillance, risk management\u003c\/td\u003e\n \u003ctd\u003eProtects trust and supports long-term product use\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch collaboration with trial centers\u003c\/td\u003e\n \u003ctd\u003eAcademic medical centers, investigators, clinical research sites\u003c\/td\u003e\n \u003ctd\u003eProtocol support, study execution, investigator engagement, data generation\u003c\/td\u003e\n \u003ctd\u003eStrengthens evidence generation and clinician relationships\u003c\/td\u003e\n \u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003ePhysician and specialist engagement\u003c\/strong\u003e is the core relationship layer. Amgen sells biologic and specialty medicines that are prescribed mainly by specialists, not by general consumer demand. That makes scientific credibility, peer review, and clinical data more important than mass advertising. In practice, the relationship is built through medical education, field-based account support, and ongoing dialogue about patient selection, dosing, administration, and monitoring.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eSpecialist relationships influence whether a therapy is started, continued, or switched.\u003c\/li\u003e\n \u003cli\u003eLong-term treatment areas make repeat interaction more valuable than one-time selling.\u003c\/li\u003e\n \u003cli\u003eClinical familiarity helps prescribers manage safety, adherence, and follow-up.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003ePatient access support via AmgenNow\u003c\/strong\u003e is the main patient-facing relationship channel. Specialty medicines often face insurance review, step edits, and out-of-pocket cost pressure, so access support is part of the product experience, not an extra service. AmgenNow helps patients and office staff move from prescription to approved treatment, which matters most when therapy cannot start until coverage is confirmed.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eBenefits verification helps offices see what the insurer will pay before treatment starts.\u003c\/li\u003e\n \u003cli\u003ePrior authorization support helps reduce administrative delays.\u003c\/li\u003e\n \u003cli\u003eFinancial assistance can lower abandonment when patient cost exposure is high.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eMedical affairs and market access teams\u003c\/strong\u003e keep the relationship both scientific and reimbursable. Medical affairs speaks to evidence, clinical use, and disease education. Market access speaks to payer value, formulary placement, and budget impact. This dual structure matters because a medicine can have clinical demand but still fail commercially if coverage is weak or reimbursement is slow.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eMedical affairs supports evidence-based dialogue with clinicians and institutions.\u003c\/li\u003e\n \u003cli\u003eMarket access supports payer reviews and coverage decisions.\u003c\/li\u003e\n \u003cli\u003eFor a company with \u003cstrong\u003e$28.2 billion\u003c\/strong\u003e in 2023 net sales, reimbursement quality directly affects realized revenue.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOngoing post-launch safety monitoring\u003c\/strong\u003e is part of the customer relationship because specialty biologics are often used for years. Amgen must keep collecting adverse-event reports, monitor safety signals, and meet post-marketing obligations where required. That process matters to physicians because it tells them whether real-world use matches the clinical trial profile.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eSafety monitoring supports physician confidence after approval.\u003c\/li\u003e\n \u003cli\u003eIt helps regulators and prescribers evaluate long-term use.\u003c\/li\u003e\n \u003cli\u003eIt reduces the risk of trust loss from unmanaged safety concerns.\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eResearch collaboration with trial centers\u003c\/strong\u003e starts before launch and continues after launch. Amgen works with academic centers and clinical investigators to run studies, generate evidence, and refine how therapies are used in practice. These relationships matter because the same centers that run trials often influence guidelines, specialist opinion, and future prescribing patterns.\u003c\/p\u003e\n\n\u003cul\u003e\n\u003cli\u003eTrial-center partnerships support patient recruitment and protocol execution.\u003c\/li\u003e\n \u003cli\u003eInvestigators become long-term scientific partners for future studies.\u003c\/li\u003e\n \u003cli\u003eClinical evidence from these centers helps support physician and payer confidence.\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eAmgen Inc. - Canvas Business Model: Channels\u003c\/h2\u003e\n\u003cp\u003eAmgen Inc. uses \u003cstrong\u003e4\u003c\/strong\u003e channel layers: hospitals and specialty clinics, specialty pharmacies and distributors, a direct commercial sales force, and U.S.\/EU regulatory access. The channel design is built around fixed-dose biologics such as \u003cstrong\u003e60 mg\u003c\/strong\u003e every \u003cstrong\u003e6 months\u003c\/strong\u003e, \u003cstrong\u003e120 mg\u003c\/strong\u003e every \u003cstrong\u003e4 weeks\u003c\/strong\u003e, \u003cstrong\u003e210 mg\u003c\/strong\u003e every \u003cstrong\u003e4 weeks\u003c\/strong\u003e, and \u003cstrong\u003e28-day\u003c\/strong\u003e infusion cycles.\u003c\/p\u003e\n\n\u003cp\u003eHospitals and specialty clinics handle the products that need administration by a healthcare professional, infusion monitoring, or step-up dosing. Blincyto uses continuous intravenous infusion over \u003cstrong\u003e28 days\u003c\/strong\u003e; Xgeva is given as \u003cstrong\u003e120 mg\u003c\/strong\u003e every \u003cstrong\u003e4 weeks\u003c\/strong\u003e; Evenity is \u003cstrong\u003e210 mg\u003c\/strong\u003e monthly for \u003cstrong\u003e12 months\u003c\/strong\u003e; Prolia is \u003cstrong\u003e60 mg\u003c\/strong\u003e every \u003cstrong\u003e6 months\u003c\/strong\u003e; Imdelltra uses a step-up dose of \u003cstrong\u003e1 mg\u003c\/strong\u003e followed by \u003cstrong\u003e10 mg\u003c\/strong\u003e every \u003cstrong\u003e2 weeks\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eBlincyto: continuous IV infusion over \u003cstrong\u003e28 days\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eXgeva: \u003cstrong\u003e120 mg\u003c\/strong\u003e every \u003cstrong\u003e4 weeks\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eEvenity: \u003cstrong\u003e210 mg\u003c\/strong\u003e every \u003cstrong\u003e4 weeks\u003c\/strong\u003e for \u003cstrong\u003e12 months\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eProlia: \u003cstrong\u003e60 mg\u003c\/strong\u003e every \u003cstrong\u003e6 months\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eImdelltra: \u003cstrong\u003e1 mg\u003c\/strong\u003e step-up dose, then \u003cstrong\u003e10 mg\u003c\/strong\u003e every \u003cstrong\u003e2 weeks\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eProduct\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eChannel setting\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNumeric administration detail\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eU.S. approval date\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBlincyto\u003c\/td\u003e\n\u003ctd\u003eHospital, infusion center, specialty clinic\u003c\/td\u003e\n\u003ctd\u003eContinuous IV infusion over \u003cstrong\u003e28 days\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2014-12-03\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eXgeva\u003c\/td\u003e\n\u003ctd\u003eSpecialty clinic\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e120 mg\u003c\/strong\u003e every \u003cstrong\u003e4 weeks\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2010-11-18\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEvenity\u003c\/td\u003e\n\u003ctd\u003eSpecialty clinic\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e210 mg\u003c\/strong\u003e every \u003cstrong\u003e4 weeks\u003c\/strong\u003e for \u003cstrong\u003e12 months\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2019-04-09\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProlia\u003c\/td\u003e\n\u003ctd\u003eSpecialty clinic\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e60 mg\u003c\/strong\u003e every \u003cstrong\u003e6 months\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2010-06-02\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eImdelltra\u003c\/td\u003e\n\u003ctd\u003eHospital, infusion center\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e1 mg\u003c\/strong\u003e step-up dose, then \u003cstrong\u003e10 mg\u003c\/strong\u003e every \u003cstrong\u003e2 weeks\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003e2024-05-16\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eSpecialty pharmacies and distributors carry the products that move through the pharmacy benefit and need cold-chain or refill coordination. Repatha is dispensed as \u003cstrong\u003e140 mg\u003c\/strong\u003e every \u003cstrong\u003e2 weeks\u003c\/strong\u003e or \u003cstrong\u003e420 mg\u003c\/strong\u003e monthly; Otezla is dosed at \u003cstrong\u003e30 mg\u003c\/strong\u003e twice daily after titration; Tezspire is \u003cstrong\u003e210 mg\u003c\/strong\u003e every \u003cstrong\u003e4 weeks\u003c\/strong\u003e. For biologics in this channel, shipment conditions commonly run at \u003cstrong\u003e2°C to 8°C\u003c\/strong\u003e.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003eRepatha: \u003cstrong\u003e140 mg\u003c\/strong\u003e every \u003cstrong\u003e2 weeks\u003c\/strong\u003e or \u003cstrong\u003e420 mg\u003c\/strong\u003e monthly\u003c\/li\u003e\n\u003cli\u003eOtezla: \u003cstrong\u003e30 mg\u003c\/strong\u003e twice daily after titration\u003c\/li\u003e\n\u003cli\u003eTezspire: \u003cstrong\u003e210 mg\u003c\/strong\u003e every \u003cstrong\u003e4 weeks\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003eCold-chain range: \u003cstrong\u003e2°C to 8°C\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003eThe direct commercial sales force is organized around specialty call points rather than retail volume. The channel footprint spans \u003cstrong\u003e50\u003c\/strong\u003e U.S. states, \u003cstrong\u003e27\u003c\/strong\u003e EU member states, and more than \u003cstrong\u003e100\u003c\/strong\u003e countries, which matches Amgen Inc.'s mix of oncology, bone health, cardiovascular, inflammation, and rare disease products.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003e\u003cstrong\u003eRegulatory region\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eNumeric access scope\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eAuthority\u003c\/strong\u003e\u003c\/td\u003e\n\u003ctd\u003e\u003cstrong\u003eChannel effect\u003c\/strong\u003e\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eUnited States\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e50\u003c\/strong\u003e states\u003c\/td\u003e\n\u003ctd\u003eFDA\u003c\/td\u003e\n\u003ctd\u003eNational commercial launch after approval\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eEuropean Union\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e27\u003c\/strong\u003e member states\u003c\/td\u003e\n\u003ctd\u003eEMA review and European Commission authorization\u003c\/td\u003e\n\u003ctd\u003eOne centralized authorization can cover \u003cstrong\u003e27\u003c\/strong\u003e markets\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003eAmgen Inc.'s U.S. and EU regulatory channel is a launch gate, not just a formality. One FDA approval opens the U.S. market; one centralized EU authorization can open \u003cstrong\u003e27\u003c\/strong\u003e member states. Imdelltra received FDA accelerated approval on \u003cstrong\u003e2024-05-16\u003c\/strong\u003e; Tezspire, Repatha, Prolia, Xgeva, Evenity, and Blincyto all depend on this same approval-to-access path before field sales and pharmacy fulfillment can scale.\u003c\/p\u003e\n\n\u003cp\u003eDigital and AI-enabled access platforms sit between the prescriber, the payer, and the dispensing channel. The core workflow is benefits verification, prior authorization, copay support, and refill tracking across the \u003cstrong\u003e2\u003c\/strong\u003e main payment paths: medical benefit and pharmacy benefit.\u003c\/p\u003e\n\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e payment paths: medical benefit and pharmacy benefit\u003c\/li\u003e\n\u003cli\u003eBenefits verification\u003c\/li\u003e\n\u003cli\u003ePrior authorization\u003c\/li\u003e\n\u003cli\u003eCopay support\u003c\/li\u003e\n\u003cli\u003eRefill tracking\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eAmgen Inc. - Canvas Business Model: Customer Segments\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e2,001,140\u003c\/strong\u003e new U.S. cancer cases, \u003cstrong\u003e611,720\u003c\/strong\u003e cancer deaths, \u003cstrong\u003e10 million\u003c\/strong\u003e U.S. osteoporosis cases, \u003cstrong\u003e44 million\u003c\/strong\u003e U.S. adults with low bone mass, \u003cstrong\u003e40.3%\u003c\/strong\u003e U.S. adult obesity prevalence, and a rare-disease cutoff of fewer than \u003cstrong\u003e200,000\u003c\/strong\u003e U.S. patients per condition define the main customer pools for Amgen Inc. in late 2025.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003cth\u003eCustomer segment\u003c\/th\u003e\n\u003cth\u003eReal-life numeric marker\u003c\/th\u003e\n\u003cth\u003eBuyer or gatekeeper\u003c\/th\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCancer patients and oncologists\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e2,001,140\u003c\/strong\u003e new U.S. cases; \u003cstrong\u003e611,720\u003c\/strong\u003e deaths; \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eOncologists; cancer centers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare disease patients and specialists\u003c\/td\u003e\n\u003ctd\u003eFewer than \u003cstrong\u003e200,000\u003c\/strong\u003e patients per U.S. rare disease; NMOSD \u003cstrong\u003e1 to 10 per 100,000\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003eSpecialists; tertiary centers\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOsteoporosis and bone disease patients\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e10 million\u003c\/strong\u003e osteoporosis; \u003cstrong\u003e44 million\u003c\/strong\u003e low bone mass; \u003cstrong\u003e1 in 2\u003c\/strong\u003e women and \u003cstrong\u003e1 in 4\u003c\/strong\u003e men over \u003cstrong\u003e50\u003c\/strong\u003e\n\u003c\/td\u003e\n\u003ctd\u003ePrimary care; endocrinology; orthopedics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCardiovascular and obesity treatment markets\u003c\/td\u003e\n\u003ctd\u003e\n\u003cstrong\u003e40.3%\u003c\/strong\u003e obesity; \u003cstrong\u003e9.4%\u003c\/strong\u003e severe obesity; \u003cstrong\u003e1 in 250\u003c\/strong\u003e familial hypercholesterolemia\u003c\/td\u003e\n\u003ctd\u003eCardiologists; lipid clinics; obesity specialists\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003ePayers, providers, and health systems\u003c\/td\u003e\n\u003ctd\u003eMore than \u003cstrong\u003e65 million\u003c\/strong\u003e Medicare beneficiaries; more than \u003cstrong\u003e70 million\u003c\/strong\u003e Medicaid and CHIP enrollees\u003c\/td\u003e\n\u003ctd\u003ePayers; hospitals; integrated delivery systems\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCancer patients and oncologists\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e2,001,140\u003c\/strong\u003e U.S. new cancer cases in \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e611,720\u003c\/strong\u003e U.S. cancer deaths in \u003cstrong\u003e2024\u003c\/strong\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e2\u003c\/strong\u003e large demand signals: incidence and mortality\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eRare disease patients and specialists\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eFewer than \u003cstrong\u003e200,000\u003c\/strong\u003e U.S. patients per rare disease\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1 to 10 per 100,000\u003c\/strong\u003e prevalence range for neuromyelitis optica spectrum disorder\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e200,000\u003c\/strong\u003e is the U.S. rare-disease cutoff\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOsteoporosis and bone disease patients\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e10 million\u003c\/strong\u003e U.S. adults with osteoporosis\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e44 million\u003c\/strong\u003e U.S. adults with low bone mass\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1 in 2\u003c\/strong\u003e women and \u003cstrong\u003e1 in 4\u003c\/strong\u003e men over \u003cstrong\u003e50\u003c\/strong\u003e will break a bone because of osteoporosis\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eCardiovascular and obesity treatment markets\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e40.3%\u003c\/strong\u003e U.S. adult obesity prevalence\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e9.4%\u003c\/strong\u003e U.S. adult severe obesity prevalence\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e1 in 250\u003c\/strong\u003e people with familial hypercholesterolemia\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003ePayers, providers, and health systems\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eMore than \u003cstrong\u003e65 million\u003c\/strong\u003e Medicare beneficiaries\u003c\/li\u003e\n\u003cli\u003eMore than \u003cstrong\u003e70 million\u003c\/strong\u003e Medicaid and CHIP enrollees\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e200,000\u003c\/strong\u003e patient threshold for rare-disease coverage decisions\u003c\/li\u003e\n\u003c\/ul\u003e\u003ch2\u003eAmgen Inc. - Canvas Business Model: Cost Structure\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$33.4 billion\u003c\/strong\u003e revenue, \u003cstrong\u003e$9.3 billion\u003c\/strong\u003e cost of sales, \u003cstrong\u003e$5.4 billion\u003c\/strong\u003e research and development, \u003cstrong\u003e$5.9 billion\u003c\/strong\u003e selling, general and administrative, \u003cstrong\u003e$20.6 billion\u003c\/strong\u003e operating costs, \u003cstrong\u003e$12.8 billion\u003c\/strong\u003e operating income, \u003cstrong\u003e$27.8 billion\u003c\/strong\u003e Horizon acquisition purchase price.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost structure item\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003eShare of $33.4 billion revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCost of sales\u003c\/td\u003e\n\u003ctd\u003e$9.3 billion\u003c\/td\u003e\n\u003ctd\u003e27.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eResearch and development\u003c\/td\u003e\n\u003ctd\u003e$5.4 billion\u003c\/td\u003e\n\u003ctd\u003e16.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSelling, general and administrative\u003c\/td\u003e\n\u003ctd\u003e$5.9 billion\u003c\/td\u003e\n\u003ctd\u003e17.7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal of these operating costs\u003c\/td\u003e\n\u003ctd\u003e$20.6 billion\u003c\/td\u003e\n\u003ctd\u003e61.7%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOperating income\u003c\/td\u003e\n\u003ctd\u003e$12.8 billion\u003c\/td\u003e\n\u003ctd\u003e38.3%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003e$5.4 billion\u003c\/strong\u003e research and development\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$9.3 billion\u003c\/strong\u003e cost of sales\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$5.9 billion\u003c\/strong\u003e selling, general and administrative\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003e$27.8 billion\u003c\/strong\u003e acquisition purchase price\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eBucket\u003c\/td\u003e\n\u003ctd\u003eAmount\u003c\/td\u003e\n\u003ctd\u003eDisclosed line\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eHeavy R\u0026amp;D spending\u003c\/td\u003e\n\u003ctd\u003e$5.4 billion\u003c\/td\u003e\n\u003ctd\u003eResearch and development\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eManufacturing and capacity expansion\u003c\/td\u003e\n\u003ctd\u003e$9.3 billion\u003c\/td\u003e\n\u003ctd\u003eCost of sales\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSales, marketing, and medical affairs\u003c\/td\u003e\n\u003ctd\u003e$5.9 billion\u003c\/td\u003e\n\u003ctd\u003eSelling, general and administrative\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory, compliance, and legal\u003c\/td\u003e\n\u003ctd\u003e$5.9 billion\u003c\/td\u003e\n\u003ctd\u003eSelling, general and administrative\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAI and digital infrastructure\u003c\/td\u003e\n\u003ctd\u003e$5.9 billion\u003c\/td\u003e\n\u003ctd\u003eSelling, general and administrative\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\u003ch2\u003eAmgen Inc. - Canvas Business Model: Revenue Streams\u003c\/h2\u003e\n\u003cp\u003e\u003cstrong\u003e$33,424 million\u003c\/strong\u003e total revenue, \u003cstrong\u003e$32,835 million\u003c\/strong\u003e product sales, \u003cstrong\u003e$589 million\u003c\/strong\u003e other revenue, \u003cstrong\u003e98.2%\u003c\/strong\u003e product-sales mix, \u003cstrong\u003e1.8%\u003c\/strong\u003e other-revenue mix.\u003c\/p\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eRevenue stream\u003c\/td\u003e\n\u003ctd\u003e2024 amount\u003c\/td\u003e\n\u003ctd\u003eShare of total revenue\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eProduct sales\u003c\/td\u003e\n\u003ctd\u003e$32,835 million\u003c\/td\u003e\n\u003ctd\u003e98.2%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOther revenue\u003c\/td\u003e\n\u003ctd\u003e$589 million\u003c\/td\u003e\n\u003ctd\u003e1.8%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTotal revenue\u003c\/td\u003e\n\u003ctd\u003e$33,424 million\u003c\/td\u003e\n\u003ctd\u003e100.0%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eProduct sales from key brands\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eProlia\u003c\/li\u003e\n\u003cli\u003eEnbrel\u003c\/li\u003e\n\u003cli\u003eRepatha\u003c\/li\u003e\n\u003cli\u003eOtezla\u003c\/li\u003e\n\u003cli\u003eXgeva\u003c\/li\u003e\n\u003cli\u003eEvenity\u003c\/li\u003e\n\u003cli\u003eKyprolis\u003c\/li\u003e\n\u003cli\u003eNplate\u003c\/li\u003e\n\u003cli\u003eBLINCYTO\u003c\/li\u003e\n\u003cli\u003eTEZSPIRE\u003c\/li\u003e\n\u003cli\u003eMvasi\u003c\/li\u003e\n\u003cli\u003eKanjinti\u003c\/li\u003e\n\u003cli\u003eVectibix\u003c\/li\u003e\n\u003cli\u003eParsabiv\u003c\/li\u003e\n\u003cli\u003eLumakras\/Lumykras\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003cp\u003e\u003cstrong\u003eOncology and rare disease therapies\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eTherapy group\u003c\/td\u003e\n\u003ctd\u003eBrands\u003c\/td\u003e\n\u003ctd\u003eCount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eOncology\u003c\/td\u003e\n\u003ctd\u003eKyprolis, BLINCYTO, Vectibix, Lumakras\/Lumykras\u003c\/td\u003e\n\u003ctd\u003e4\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRare disease\u003c\/td\u003e\n\u003ctd\u003eTEPEZZA, KRYSTEXXA\u003c\/td\u003e\n\u003ctd\u003e2\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eCardiovascular and bone health products\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003eCardiovascular: Repatha\u003c\/li\u003e\n\u003cli\u003eBone health: Prolia, Xgeva, Evenity\u003c\/li\u003e\n\u003c\/ul\u003e\n\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eCategory\u003c\/td\u003e\n\u003ctd\u003eBrands\u003c\/td\u003e\n\u003ctd\u003eCount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCardiovascular\u003c\/td\u003e\n\u003ctd\u003eRepatha\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eBone health\u003c\/td\u003e\n\u003ctd\u003eProlia, Xgeva, Evenity\u003c\/td\u003e\n\u003ctd\u003e3\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eBiosimilar sales\u003c\/strong\u003e\u003c\/p\u003e\n\u003ctable\u003e\n\u003ctr\u003e\n\u003ctd\u003eBiosimilar brand\u003c\/td\u003e\n\u003ctd\u003eReference product\u003c\/td\u003e\n\u003ctd\u003eCount\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAmjevita\u003c\/td\u003e\n\u003ctd\u003eAdalimumab\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eMVASI\u003c\/td\u003e\n\u003ctd\u003eBevacizumab\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eKANJINTI\u003c\/td\u003e\n\u003ctd\u003eTrastuzumab\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAMGEVITA\u003c\/td\u003e\n\u003ctd\u003eAdalimumab\u003c\/td\u003e\n\u003ctd\u003e1\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/table\u003e\n\n\u003cp\u003e\u003cstrong\u003eInternational product sales\u003c\/strong\u003e\u003c\/p\u003e\n\u003cp\u003e\u003cstrong\u003e$32,835 million\u003c\/strong\u003e product sales base includes non-U.S. sales for Repatha, Prolia, Xgeva, TEZSPIRE, and the biosimilar portfolio.\u003c\/p\u003e","brand":"dcf.fm","offers":[{"title":"Default Title","offer_id":44601582977173,"sku":"amgn-business-model-canvas","price":7.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0630\/5189\/0837\/files\/amgn-business-model-canvas.png?v=1740145940","url":"https:\/\/dcf-analysis.com\/products\/amgn-business-model-canvas","provider":"AI-Powered Discounted Cash Flow Model Templates","version":"1.0","type":"link"}